Klaus Krueger
About
Klaus Krueger is a scholar working on Rheumatology, Hematology and Immunology.
According to data from OpenAlex, Klaus Krueger has authored 21 papers receiving a total of 565 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 5 papers in Hematology and 5 papers in Immunology. Recurrent topics in Klaus Krueger's work include Rheumatoid Arthritis Research and Therapies (11 papers), Autoimmune and Inflammatory Disorders Research (5 papers) and Spondyloarthritis Studies and Treatments (4 papers). Klaus Krueger is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (11 papers), Autoimmune and Inflammatory Disorders Research (5 papers) and Spondyloarthritis Studies and Treatments (4 papers). Klaus Krueger collaborates with scholars based in Germany, Switzerland and Estonia. Klaus Krueger's co-authors include Stanisław Sierakowski, Frank Buttgereit, Erika Gromnica‐Ihle, Jacek Szechiński, Sławomir Jeka, Rieke Alten, Stephan Witte, Stefan Kleinert, R. Alten and Gabriele Doering and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and Lara D. Veeken.
In The Last Decade
Klaus Krueger
21 papers receiving 538 citations
Peers
Klaus Krueger
Suzanne Droesch France
Henriette P. Sennels Denmark
Ursula Hanusch‐Enserer Austria
Rıdvan Yalçin Türkiye
Camilla H. Sandholt Denmark
Paraskevi Rodopoulou Greece
María Fernanda Garcés Colombia
Ioannis Papadopoulos Greece
Arun Changolkar United States
Lauren E. Mokry Canada
Citations per year, relative to Klaus Krueger Klaus Krueger (= 1×)
peers
Suzanne Droesch
Countries citing papers authored by Klaus Krueger
Since
Specialization
Citations
This map shows the geographic impact of Klaus Krueger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Krueger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Krueger more than expected).
Fields of papers citing papers by Klaus Krueger
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Klaus Krueger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Krueger. The network helps show where Klaus Krueger may publish in the future.
Co-authorship network of co-authors of Klaus Krueger
This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Krueger. A scholar is included among the top collaborators of Klaus Krueger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Krueger. Klaus Krueger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fiehn, Christoph, C. Kneitz, Francesco De Leonardis, et al.. (2023). POS0851 REAL-WORLD EXPERIENCE WITH FILGOTINIB (FIL) FOR RHEUMATOID ARTHRITIS (RA) IN GERMANY: A RETROSPECTIVE CHART REVIEW. Annals of the Rheumatic Diseases. 82. 727–728.
2.
Albrecht, Katinka, K. Thiele, Martin Aringer, et al.. (2023). POS1090 IMPLEMENTATION OF QUALITY STANDARDS FOR HEALTH CARE OF PATIENTS WITH RHEUMATOID ARTHRITIS: FIRST RESULTS FROM THE NATIONAL DATABASE OF THE GERMAN COLLABORATIVE ARTHRITIS CENTRES. Annals of the Rheumatic Diseases. 82. 868–869.
3.
Foldenauer, Ann Christina, Rieke Alten, Martin Aringer, et al.. (2022). Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). Journal of Clinical Medicine. 11(24). 7316–7316.
4.
Behrens, Frank, Rieke Alten, Martin Aringer, et al.. (2021). Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). Lara D. Veeken. 60(11). 5318–5328.
5.
Schulze‐Koops, Hendrik, et al.. (2020). Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al’ by Benucci et al. Annals of the Rheumatic Diseases. 81(9). e185–e185.
6.
Orbai, Ana‐Maria, Klaus Krueger, Frank Behrens, et al.. (2019). AB0773 PSORIATIC ARTHRITIS IMPACT OF DISEASE QUESTIONNAIRE SCORES ARE CORRELATED WITH DISEASE ACTIVITY, AS MEASURED BY CDAPSA, IN PATIENTS WITH PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 78. 1856–1856.
7.
Krueger, Klaus, et al.. (2019). SAT0166 GOLIMUMAB AS FIRST, SECOND OR AT LEAST THIRD BIOLOGIC AGENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) OR ANKYLOSING SPONDYLITIS (AS) – POST HOC ANALYSIS OF A NON-INTERVENTIONAL STUDY IN GERMANY. Annals of the Rheumatic Diseases. 78. 1156–1157.
8.
Krueger, Klaus, et al.. (2019). FRI0103 BENEFIT STUDY: A PAN-EUROPEAN OBSERVATIONAL STUDY TO EVALUATE REAL-WORLD EFFECTIVENESS OF SB4 FOLLOWING TRANSITION FROM ORIGINATOR ETANERCEPT (ETN) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) OR AXIAL SPONDYLOARTHRITIS (AXSPA). Annals of the Rheumatic Diseases. 78. 717–718.
9.
Krueger, Klaus, et al.. (2018). SAT0187 Golimumab improves work productivity and activity impairment in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PSA): 1-year results from a non- interventional trial in germany. Annals of the Rheumatic Diseases. 77. 954–955.
10.
Krueger, Klaus, et al.. (2018). OP0137 Assessing the risk of ra patients for comorbid conditions through a structured nurse-led interview – the eriko study. Annals of the Rheumatic Diseases. 77. 119–119.
11.
Englbrecht, Matthias, Rieke Alten, Martin Aringer, et al.. (2016). Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge. Arthritis Care & Research. 69(1). 58–66.
12.
Mueller, S., Klaus Krueger, Jan-Paul Flacke, et al.. (2015). Non-Adherence and Non-Persistence Should be Analyzed Separately: The Example of Methotrexate (Mtx) Therapy in the Therapy of Newly Treated Rheumatoid Arthritis in Germany. Value in Health. 18(7). A719–A719.
13.
Kleinert, Stefan, H-P Tony, Klaus Krueger, et al.. (2012). Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Annals of the Rheumatic Diseases. 71(11). 1791–1795.
14.
Kleinert, Stefan, Klaus Krueger, & Stefan Störk. (2012). Atheroskleroserisiko durch Inflammation bei rheumatoider Arthritis. Zeitschrift für Rheumatologie. 71(10). 850–858.
15.
Kleinert, Stefan & Klaus Krueger. (2011). Kardiovaskuläre Komorbidität und ihre Risikofaktoren bei rheumatoider Arthritis. Zeitschrift für Rheumatologie. 70(6). 464–472.
16.
Buttgereit, Frank, Gabriele Doering, Stanisław Sierakowski, et al.. (2010). Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Annals of the Rheumatic Diseases. 69(7). 1275–1280.
17.
Emery, Paul, Ronald van Vollenhoven, M. Østergaard, et al.. (2009). Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Annals of the Rheumatic Diseases. 68(4). 456–459.
18.
Buttgereit, Frank, Stephan Witte, Stanisław Sierakowski, et al.. (2008). Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. The Lancet. 371(9608). 205–214.
19.
Krueger, Klaus, Robin K. Dore, S. Radominski, et al.. (2007). Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Annals of the Rheumatic Diseases. 67(3). 315–322.
20.
Zimmermann, G. & Klaus Krueger. (1963). [ULTRACENTRIFUGE STUDIES ON PROPERDIN SERA OF ZYMOSAN-VACCINATED CATTLE, RABBITS, GUINEA PIGS, RATS AND MICE AND ON BOVINE PROPERDIN SERUM FRACTIONS].. PubMed. 11. 902–17.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Suzanne Droesch Breakdown of academic impact, for papers by Henriette P. Sennels Breakdown of academic impact, for papers by Ursula Hanusch‐Enserer Breakdown of academic impact, for papers by Rıdvan Yalçin Breakdown of academic impact, for papers by Camilla H. Sandholt Breakdown of academic impact, for papers by Paraskevi Rodopoulou Breakdown of academic impact, for papers by María Fernanda Garcés Breakdown of academic impact, for papers by Ioannis Papadopoulos Breakdown of academic impact, for papers by Arun Changolkar Breakdown of academic impact, for papers by Lauren E. Mokry